financetom
Business
financetom
/
Business
/
Elliott defends Citgo offer in the face of creditors' objections
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Elliott defends Citgo offer in the face of creditors' objections
Oct 22, 2024 12:49 PM

*

Hedge fund unit has Barclays ( JJCTF ), Citibank debt commitment

letter

*

Says Citgo assets 'deteriorating', urges acceptance of its

bid

By Gary McWilliams

HOUSTON, Oct 21 (Reuters) - Hedge fund Elliott

Investment Management on Monday pressed a court not to hold up

its bid for Citgo Petroleum, saying the Venezuela-owned oil

refiner's assets "are deteriorating in value" and creditors will

not get a better offer from others.

The comments came in a court filing after creditors last

week described an up to $7.3 billion conditional bid placed

before the court by Elliott's wholly-owned Amber Energy as

inadequate and likely to be rejected.

Elliott's wholly-owned Amber Energy repeated its threat to

walk away if the court "does not address threshold issues,"

referring to its desire to hold back more than $2 billion of its

offer as a set-aside were Venezuela bondholders to prevail in a

separate lawsuit. And it wants the court to bar other lawsuits

from seeking control over the same assets.

Citgo operates three U.S. refineries, 38

terminals, six pipelines and supplies fuel to 4,200 independent

retailers. The Houston-based oil refiner is the centerpiece in a

U.S. District Court in Delaware's auction seeking to satisfy $21

billion in claims against Venezuela for defaults and

expropriations.

In addition to Eliott's backing, Amber wrote it has obtained

a debt commitment letter from Barclays ( JJCTF ) and Citigroup ( C/PN )

's Citibank demonstrating its ability to finance the

purchase. It also has retained an eight person refining

management team ready to take over Citgo operations.

The court filing did not address other issues raised by

creditors, including an undisclosed breakup fee should the deal

not conclude, and opposition to other bidders accessing Citgo

financial data until after the court decides on its breakup fee.

A spokesperson declined to respond to those issues.

Amber wrote its proposal is "the best and only realistic

pathway for the largest number of creditors" to receive payment

despite creditors calling its terms as unlikely to provide them

with auction proceeds "for years - if ever."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Nov 4, 2024
(Reuters) - Vertex Pharmaceuticals ( VRTX ) raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion. Analysts expect annual revenue of $10.75 billion, according to...
--Vertex Pharmaceuticals Raises Full Year 2024 Product Revenue Guidance to $10.8-$10.9 Billion, vs Prior View of $10.65-$10.85 Billion
--Vertex Pharmaceuticals Raises Full Year 2024 Product Revenue Guidance to $10.8-$10.9 Billion, vs Prior View of $10.65-$10.85 Billion
Nov 4, 2024
04:03 PM EST, 11/04/2024 (MT Newswires) -- Price: 468.00, Change: -3.12, Percent Change: -0.66 ...
Diamondback Energy misses estimates for third-quarter profit
Diamondback Energy misses estimates for third-quarter profit
Nov 4, 2024
Nov 4 (Reuters) - Diamondback Energy ( FANG ) missed estimates for third-quarter profit on Monday as the oil and gas firm was hurt by lower prices. The company reported an adjusted profit of $3.38 per share for the quarter ended Sept. 30, compared with analysts' average estimate of $3.98 per share, according to data compiled by LSEG. (Reporting by...
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Nov 4, 2024
Nov 4 (Reuters) - Vertex Pharmaceuticals ( VRTX ) raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion. Analysts expect annual revenue of $10.75 billion,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved